Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Arcus Biosciences (RCUS) Net Income towards Common Stockholders: 2017-2024

Historic Net Income towards Common Stockholders for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to -$283.0 million.

  • Arcus Biosciences' Net Income towards Common Stockholders fell 46.74% to -$135.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$433.0 million, marking a year-over-year decrease of 60.37%. This contributed to the annual value of -$283.0 million for FY2024, which is 7.82% up from last year.
  • As of FY2024, Arcus Biosciences' Net Income towards Common Stockholders stood at -$283.0 million, which was up 7.82% from -$307.0 million recorded in FY2023.
  • In the past 5 years, Arcus Biosciences' Net Income towards Common Stockholders ranged from a high of $53.0 million in FY2021 and a low of -$307.0 million during FY2023.
  • Over the past 3 years, Arcus Biosciences' median Net Income towards Common Stockholders value was -$283.0 million (recorded in 2024), while the average stood at -$285.7 million.
  • In the last 5 years, Arcus Biosciences' Net Income towards Common Stockholders spiked by 143.09% in 2021 and then plummeted by 603.77% in 2022.
  • Arcus Biosciences' Net Income towards Common Stockholders (Yearly) stood at -$123.0 million in 2020, then soared by 143.09% to $53.0 million in 2021, then tumbled by 603.77% to -$267.0 million in 2022, then declined by 14.98% to -$307.0 million in 2023, then grew by 7.82% to -$283.0 million in 2024.